Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Anti-Cancer Drug Discovery
  4. Fast Track Articles
  5. Fast Track Article
image of Covalent Inhibitor Screening for Targeting LOXL2: Studied by Virtual Screening and Experimental Validation

Abstract

Background

Lysyl oxidase-like 2 (LOXL2) is a metalloenzyme that catalyzes oxidative deamination ε-amino group of lysine. It has been found that LOXL2 is a promotor for the metastasis and invasion in kinds of tumors. Previous studies show that disulfide bonds are important components in LOXL2, and their bioactivity can be regulated by those bonds. In this way, a small molecule covalently binds to the thiol group of cysteine residue could be an effective way to change the function of LOXL2 by blocking the formation of the disulfide bond.

Objective

This investigation is aiming to screen covalent inhibitor for LOXL2.

Methods

Covalent molecule libraries of Life Chemical and Enamine were used. The structures of those molecules were optimized by using LigPrep module of Schrödinger. Then optimized by using the LigPrep module of Schrödinger to generate optimal conformations. For covalent docking, in Glide module was used for the virtual screening. Finally, wound-healing assays were performed to examine the effects of the potential inhibitors.

Results

Eight potential small molecules were selected by covalent docking from the databases (in total 7,908 candidates). ADMET evaluation indicated that all those eight small molecules satisfy the general standard. Furthermore, wound healing experiments showed that the compound (F50972176) significantly inhibits the migration of cancer cells.

Conclusion

Virtual screening and experimental verification methods were used to screen covalent inhibitors of LOXL2 by targeting functional disulfide bonds. The compound (F50972176) effectively inhibited the migration of esophageal squamous cell carcinoma cells.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928356643241216132041
2025-01-02
2025-03-02

  • From This Site

    /content/journals/pra/10.2174/0115748928356643241216132041
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kagan H.M. Li W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J. Cell. Biochem. 2003 88 4 660 672 10.1002/jcb.10413 12577300
    [Google Scholar]
  2. Vadasz Z. Kessler O. Akiri G. Gengrinovitch S. Kagan H.M. Baruch Y. Izhak O.B. Neufeld G. Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J. Hepatol. 2005 43 3 499 507 10.1016/j.jhep.2005.02.052 16023247
    [Google Scholar]
  3. Kim Y.M. Kim E.C. Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol. Biol. Rep. 2011 38 1 145 149 10.1007/s11033‑010‑0088‑0 20306300
    [Google Scholar]
  4. Csiszar K. Lysyl oxidases: A novel multifunctional amine oxidase family. Prog. Nucleic Acid Res. Mol. Biol. 2001 70 1 32 10.1016/S0079‑6603(01)70012‑8 11642359
    [Google Scholar]
  5. Ye M. Zhang J. Guo T. Pan X. MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non small cell lung cancer. Biomed. Pharmacother. 2018 97 1289 1295 10.1016/j.biopha.2017.11.005 29156517
    [Google Scholar]
  6. Peng D.H. Ungewiss C. Tong P. Byers L.A. Wang J. Canales J.R. Villalobos P.A. Uraoka N. Mino B. Behrens C. Wistuba I.I. Han R.I. Wanna C.A. Fahrenholtz M. Grande-Allen K.J. Creighton C.J. Gibbons D.L. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene 2017 36 14 1925 1938 10.1038/onc.2016.358 27694892
    [Google Scholar]
  7. Peng L. Ran Y.L. Hu H. Yu L. Liu Q. Zhou Z. Sun Y.M. Sun L.C. Pan J. Sun L.X. Zhao P. Yang Z.H. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009 30 10 1660 1669 10.1093/carcin/bgp178 19625348
    [Google Scholar]
  8. Lin Z.Y. Chuang Y.H. Chuang W.L. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed. Pharmacother. 2012 66 7 525 529 10.1016/j.biopha.2012.02.001 22739041
    [Google Scholar]
  9. Salvador F. Martin A. López-Menéndez C. Moreno-Bueno G. Santos V. Vázquez-Naharro A. Santamaría P.G. Morales S. Dubus P.R. Muinelo-Romay L. López-López R. Tung J.C. Weaver V.M. Portillo F. Cano A. Lysyl oxidase–like protein LOXL2 promotes lung metastasis of breast cancer. Cancer Res. 2017 77 21 5846 5859 10.1158/0008‑5472.CAN‑16‑3152 28720577
    [Google Scholar]
  10. Chan N. Willis A. Kornhauser N. Ward M.M. Lee S.B. Nackos E. Seo B.R. Chuang E. Cigler T. Moore A. Donovan D. Vallee Cobham M. Fitzpatrick V. Schneider S. Wiener A. Guillaume-Abraham J. Aljom E. Zelkowitz R. Warren J.D. Lane M.E. Fischbach C. Mittal V. Vahdat L. Influencing the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin. Cancer Res. 2017 23 3 666 676 10.1158/1078‑0432.CCR‑16‑1326 27769988
    [Google Scholar]
  11. Zhan X. Jiao J. Zhang H. Li C. Zhao J. Liao L. Wu J. Wu B. Wu Z. Wang S. Du Z. Shen J. Zou H. Neufeld G. Xu L. Li E. A three‐gene signature from protein–protein interaction network ofLOXL 2 ‐ and actin‐related proteins for esophageal squamous cell carcinoma prognosis. Cancer Med. 2017 6 7 1707 1719 10.1002/cam4.1096 28556501
    [Google Scholar]
  12. Zhu Y. Zhu M.X. Zhang X.D. Xu X.E. Wu Z.Y. Liao L.D. Li L.Y. Xie Y.M. Wu J.Y. Zou H.Y. Xie J.J. Li E.M. Xu L.Y. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Hum. Pathol. 2016 52 153 163 10.1016/j.humpath.2016.01.012 26980013
    [Google Scholar]
  13. Zou H.Y. Lv G.Q. Dai L.H. Zhan X.H. Jiao J.W. Liao L.D. Zhou T.M. Li C.Q. Wu B.L. Xu L.Y. Li E.M. A truncated splice variant of human lysyl oxidase-like 2 promotes migration and invasion in esophageal squamous cell carcinoma. Int. J. Biochem. Cell Biol. 2016 75 85 98 10.1016/j.biocel.2016.04.003 27063404
    [Google Scholar]
  14. Lv G.Q. Zou H.Y. Liao L.D. Cao H.H. Zeng F.M. Wu B.L. Xie J.J. Fang W.K. Xu L.Y. Li E.M. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma. Biochem. Cell Biol. 2014 92 5 379 389 10.1139/bcb‑2014‑0046 25275797
    [Google Scholar]
  15. Li T.Y. Xu L.Y. Wu Z.Y. Liao L.D. Shen J.H. Xu X.E. Du Z.P. Zhao Q. Li E.M. Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase–like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Hum. Pathol. 2012 43 7 1068 1076 10.1016/j.humpath.2011.07.027 22204712
    [Google Scholar]
  16. Choi J. Chung T. Rhee H. Kim Y.J. Jeon Y. Yoo J.E. Noh S. Han D.H. Park Y.N. Increased expression of the matrix-modifying enzyme lysyl oxidase-like 2 in aggressive hepatocellular carcinoma with poor prognosis. Gut Liver 2019 13 1 83 92 10.5009/gnl17569 29938458
    [Google Scholar]
  17. Wu L. Zhang Y. Zhu Y. Cong Q. Xiang Y. Fu L. The effect of LOXL2 in hepatocellular carcinoma. Mol. Med. Rep. 2016 14 3 1923 1932 10.3892/mmr.2016.5474 27430160
    [Google Scholar]
  18. Weaver V.M. Petersen O.W. Wang F. Larabell C.A. Briand P. Damsky C. Bissell M.J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 1997 137 1 231 245 10.1083/jcb.137.1.231 9105051
    [Google Scholar]
  19. Wiseman B.S. Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002 296 5570 1046 1049 10.1126/science.1067431 12004111
    [Google Scholar]
  20. Bissell M.J. Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001 1 1 46 54 10.1038/35094059 11900251
    [Google Scholar]
  21. Zou H. Wen B. Li R.L. Zhan X.H. Jiao J.W. Liao L.D. Wu B.L. Xie W.M. Xu L.Y. Li E.M. Lysyl oxidase-like 2 promotes esophageal squamous cell carcinoma cell migration independent of catalytic activity. Int. J. Biochem. Cell Biol. 2020 125 105795 10.1016/j.biocel.2020.105795 32580015
    [Google Scholar]
  22. Zhan X.H. Jiao J.W. Zhang H.F. Xu X.E. He J.Z. Li R.L. Zou H.Y. Wu Z.Y. Wang S.H. Wu J.Y. Liao L.D. Wang J.J. Cheng Y.W. Zhang K. Neufeld G. Xu L.Y. Li E.M. LOXL2 upregulates phosphorylation of ezrin to promote cytoskeletal reorganization and tumor cell invasion. Cancer Res. 2019 79 19 4951 4964 10.1158/0008‑5472.CAN‑19‑0860 31409639
    [Google Scholar]
  23. Barker H.E. Cox T.R. Erler J.T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 2012 12 8 540 552 10.1038/nrc3319 22810810
    [Google Scholar]
  24. Wen B. Xu L.Y. Li E.M. LOXL2 in cancer: Regulation, downstream effectors and novel roles. Biochim. Biophys. Acta Rev. Cancer 2020 1874 2 188435 10.1016/j.bbcan.2020.188435 32976981
    [Google Scholar]
  25. Chopra V. Sangarappillai R.M. Romero-Canelón I. Jones A.M. Lysyl oxidase Like‐2 (LOXL2): An emerging oncology target. Adv. Ther. 2020 3 2 1900119 10.1002/adtp.201900119
    [Google Scholar]
  26. Klepfish M. Gross T. Vugman M. Afratis N.A. Havusha-Laufer S. Brazowski E. Solomonov I. Varol C. Sagi I. LOXL2 inhibition paves the way for macrophage-mediated collagen degradation in liver fibrosis. Front. Immunol. 2020 11 480 10.3389/fimmu.2020.00480 32296422
    [Google Scholar]
  27. Rodriguez H.M. Vaysberg M. Mikels A. McCauley S. Velayo A.C. Garcia C. Smith V. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J. Biol. Chem. 2010 285 27 20964 20974 10.1074/jbc.M109.094136 20439985
    [Google Scholar]
  28. Barry-Hamilton V. Spangler R. Marshall D. McCauley S. Rodriguez H.M. Oyasu M. Mikels A. Vaysberg M. Ghermazien H. Wai C. Garcia C.A. Velayo A.C. Jorgensen B. Biermann D. Tsai D. Green J. Zaffryar-Eilot S. Holzer A. Ogg S. Thai D. Neufeld G. Van Vlasselaer P. Smith V. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nat. Med. 2010 16 9 1009 1017 10.1038/nm.2208 20818376
    [Google Scholar]
  29. Hutchinson J.H. Rowbottom M.W. Lonergan D. Darlington J. Prodanovich P. King C.D. Evans J.F. Bain G. Small molecule lysyl oxidase-like 2 (LOXL2) inhibitors: The identification of an inhibitor selective for LOXL2 over LOX. ACS Med. Chem. Lett. 2017 8 4 423 427 10.1021/acsmedchemlett.7b00014 28435530
    [Google Scholar]
  30. Schilter H. Findlay A.D. Perryman L. Yow T.T. Moses J. Zahoor A. Turner C.I. Deodhar M. Foot J.S. Zhou W. Greco A. Joshi A. Rayner B. Townsend S. Buson A. Jarolimek W. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis. J. Cell. Mol. Med. 2019 23 3 1759 1770 10.1111/jcmm.14074 30536539
    [Google Scholar]
  31. Schirmeister T. Kesselring J. Jung S. Schneider T.H. Weickert A. Becker J. Lee W. Bamberger D. Wich P.R. Distler U. Tenzer S. Johé P. Hellmich U.A. Engels B. Quantum chemical-based protocol for the rational design of covalent inhibitors. J. Am. Chem. Soc. 2016 138 27 8332 8335 10.1021/jacs.6b03052 27347738
    [Google Scholar]
  32. Bauer R.A. Covalent inhibitors in drug discovery: From accidental discoveries to avoided liabilities and designed therapies. Drug Discov. Today 2015 20 9 1061 1073 10.1016/j.drudis.2015.05.005 26002380
    [Google Scholar]
  33. Wright P.M. Seiple I.B. Myers A.G. The evolving role of chemical synthesis in antibacterial drug discovery. Angew. Chem. Int. Ed. 2014 53 34 8840 8869 10.1002/anie.201310843 24990531
    [Google Scholar]
  34. Singh J. Petter R.C. Baillie T.A. Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011 10 4 307 317 10.1038/nrd3410 21455239
    [Google Scholar]
  35. Bum-Erdene K. Zhou D. Gonzalez-Gutierrez G. Ghozayel M.K. Si Y. Xu D. Shannon H.E. Bailey B.J. Corson T.W. Pollok K.E. Wells C.D. Meroueh S.O. Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD⋅Yap protein-protein interaction. Cell Chem. Biol. 2019 26 3 378 389.e13 10.1016/j.chembiol.2018.11.010 30581134
    [Google Scholar]
  36. Schirmer A. Kennedy J. Murli S. Reid R. Santi D.V. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl. Acad. Sci. USA 2006 103 11 4234 4239 10.1073/pnas.0600445103 16537514
    [Google Scholar]
  37. Serafimova I.M. Pufall M.A. Krishnan S. Duda K. Cohen M.S. Maglathlin R.L. McFarland J.M. Miller R.M. Frödin M. Taunton J. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat. Chem. Biol. 2012 8 5 471 476 10.1038/nchembio.925 22466421
    [Google Scholar]
  38. Gauthier J.Y. Chauret N. Cromlish W. Desmarais S. Duong L.T. Falgueyret J.P. Kimmel D.B. Lamontagne S. Léger S. LeRiche T. Li C.S. Massé F. McKay D.J. Nicoll-Griffith D.A. Oballa R.M. Palmer J.T. Percival M.D. Riendeau D. Robichaud J. Rodan G.A. Rodan S.B. Seto C. Thérien M. Truong V.L. Venuti M.C. Wesolowski G. Young R.N. Zamboni R. Black W.C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 2008 18 3 923 928 10.1016/j.bmcl.2007.12.047 18226527
    [Google Scholar]
  39. Hezel A.F. Noel M.S. Allen J.N. Abrams T.A. Yurgelun M. Faris J.E. Goyal L. Clark J.W. Blaszkowsky L.S. Murphy J.E. Zheng H. Khorana A.A. Connolly G.C. Hyrien O. Baran A. Herr M. Ng K. Sheehan S. Harris D.J. Regan E. Borger D.R. Iafrate A.J. Fuchs C. Ryan D.P. Zhu A.X. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br. J. Cancer 2014 111 3 430 436 10.1038/bjc.2014.343 24960403
    [Google Scholar]
  40. Smith A.J.T. Zhang X. Leach A.G. Houk K.N. Beyond picomolar affinities: Quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med. Chem. 2009 52 2 225 233 10.1021/jm800498e 19053779
    [Google Scholar]
  41. Baillie T.A. Targeted covalent inhibitors for drug design. Angew. Chem. Int. Ed. 2016 55 43 13408 13421 10.1002/anie.201601091 27539547
    [Google Scholar]
  42. Kalgutkar A.S. Dalvie D.K. Drug discovery for a new generation of covalent drugs. Expert Opin. Drug Discov. 2012 7 7 561 581 10.1517/17460441.2012.688744 22607458
    [Google Scholar]
  43. Wu S. Luo Howard H. Wang H. Zhao W. Hu Q. Yang Y. Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors. Biochem. Biophys. Res. Commun. 2016 478 3 1268 1273 10.1016/j.bbrc.2016.08.109 27553277
    [Google Scholar]
  44. Lin L. Zou H. Li W. Xu L.Y. Li E.M. Dong G. Redox potentials of disulfide bonds in LOXL2 studied by nonequilibrium alchemical simulation. Front Chem. 2021 9 797036 10.3389/fchem.2021.797036 34970534
    [Google Scholar]
  45. McMeekin P. Lendrem D.W. Lendrem B.C. Pratt A.G. Peck R. Isaacs J.D. Jones D. Schrödinger’s pipeline and the outsourcing of pharmaceutical innovation. Drug Discov. Today 2020 25 3 480 484 10.1016/j.drudis.2019.11.015 31835019
    [Google Scholar]
  46. Roos K. Wu C. Damm W. Reboul M. Stevenson J.M. Lu C. Dahlgren M.K. Mondal S. Chen W. Wang L. Abel R. Friesner R.A. Harder E.D. OPLS3e: Extending force field coverage for drug-like small molecules. J. Chem. Theory Comput. 2019 15 3 1863 1874 10.1021/acs.jctc.8b01026 30768902
    [Google Scholar]
  47. Zhang X. Wang Q. Wu J. Wang J. Shi Y. Liu M. Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state. Proc. Natl. Acad. Sci. USA 2018 115 15 3828 3833 10.1073/pnas.1720859115 29581294
    [Google Scholar]
  48. Case D.A. Belfon K. Ben-Shalom I.Y. AMBER 2020. University of California San Francisco. 2020 10.13140/RG.2.2.25321.36969
    [Google Scholar]
  49. Bussi G. Donadio D. Parrinello M. Canonical sampling through velocity rescaling. J. Chem. Phys. 2007 126 1 014101 10.1063/1.2408420 17212484
    [Google Scholar]
  50. Parrinello M. Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 1981 52 12 7182 7190 10.1063/1.328693
    [Google Scholar]
  51. Essmann U. Perera L. Berkowitz M.L. Darden T. Lee H. Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995 103 19 8577 8593 10.1063/1.470117
    [Google Scholar]
  52. Scarpino A. Ferenczy G.G. Keserű G.M. Comparative evaluation of covalent docking tools. J. Chem. Inf. Model. 2018 58 7 1441 1458 10.1021/acs.jcim.8b00228 29890081
    [Google Scholar]
  53. Schrödinger L. The PyMOL molecular graphics system, version 1.5. Computa. Mol. Biosci. 2015 5 3 1 9
    [Google Scholar]
  54. Zhu K. Borrelli K.W. Greenwood J.R. Day T. Abel R. Farid R.S. Harder E. Docking covalent inhibitors: A parameter free approach to pose prediction and scoring. J. Chem. Inf. Model. 2014 54 7 1932 1940 10.1021/ci500118s 24916536
    [Google Scholar]
  55. Friesner R.A. Murphy R.B. Repasky M.P. Frye L.L. Greenwood J.R. Halgren T.A. Sanschagrin P.C. Mainz D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006 49 21 6177 6196 10.1021/jm051256o 17034125
    [Google Scholar]
  56. Gadakar P.K. Phukan S. Balaji V.N. Balaji V.N. Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3 beta. J. Chem. Inf. Model. 2007 47 4 1446 1459 10.1021/ci6005036 17580928
    [Google Scholar]
  57. Tubert-Brohman I. Sherman W. Repasky M. Beuming T. Improved docking of polypeptides with Glide. J. Chem. Inf. Model. 2013 53 7 1689 1699 10.1021/ci400128m 23800267
    [Google Scholar]
  58. Luo W. Pei J. Zhu Y. A fast protein-ligand docking algorithm based on hydrogen bond matching and surface shape complementarity. J. Mol. Model. 2010 16 5 903 913 10.1007/s00894‑009‑0598‑7 19823881
    [Google Scholar]
  59. Ferreira L.L.G. Andricopulo A.D. ADMET modeling approaches in drug discovery. Drug Discov. Today 2019 24 5 1157 1165 10.1016/j.drudis.2019.03.015 30890362
    [Google Scholar]
  60. Hasselgren C. Myatt G.J. Computational toxicology and drug discovery. Methods Mol. Biol. 2018 1800 233 244 10.1007/978‑1‑4939‑7899‑1_11 29934896
    [Google Scholar]
  61. Lipinski C.A. Lombardo F. Dominy B.W. Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII. Adv. Drug Deliv. Rev. 2001 46 1-3 3 26 10.1016/S0169‑409X(00)00129‑0 11259830
    [Google Scholar]
  62. Grada A. Otero-Vinas M. Prieto-Castrillo F. Obagi Z. Falanga V. Research techniques made simple: Analysis of collective cell migration using the wound healing assay. J. Invest. Dermatol. 2017 137 2 e11 e16 10.1016/j.jid.2016.11.020 28110712
    [Google Scholar]
  63. Rahman A. Muktadir M.G. SPSS: An imperative quantitative data analysis tool for social science research. Int. J. Res. Innov. Soc. Sci. 2021 5 10 300 302 10.47772/IJRISS.2021.51012
    [Google Scholar]
  64. Mitteer D.R. Greer B.D. Fisher W.W. Cohrs V.L. Teaching behavior technicians to create publication‐quality, single‐case design graphs in graphpad prism 7. J. Appl. Behav. Anal. 2018 51 4 998 1010 10.1002/jaba.483 29971776
    [Google Scholar]
  65. Halgren T.A. Murphy R.B. Friesner R.A. Beard H.S. Frye L.L. Pollard W.T. Banks J.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004 47 7 1750 1759 10.1021/jm030644s 15027866
    [Google Scholar]
  66. Chen T. Li M. Liu J. π–π stacking interaction: A nondestructive and facile means in material engineering for bioapplications. Cryst. Growth Des. 2018 18 5 2765 2783 10.1021/acs.cgd.7b01503
    [Google Scholar]
  67. Roskoski R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol. Res. 2020 152 104609 10.1016/j.phrs.2019.104609 31862477
    [Google Scholar]
  68. Benet L.Z. Hosey C.M. Ursu O. Oprea T.I. BDDCS, the Rule of 5 and drugability. Adv. Drug Deliv. Rev. 2016 101 89 98 10.1016/j.addr.2016.05.007 27182629
    [Google Scholar]
/content/journals/pra/10.2174/0115748928356643241216132041
Loading
Covalent Inhibitor Screening for Targeting LOXL2: Studied by Virtual Screening and Experimental Validation
Bentham Science Publishers ; https://doi.org/10.2174/0115748928356643241216132041
/content/journals/pra/10.2174/0115748928356643241216132041
/content/journals/pra/10.2174/0115748928356643241216132041
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: covalent inhibitor ; experimental validation ; LOXL2 ; molecular docking ; ADMET ; Disulfide bond

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test